Patients were eligible for inclusion if they had received
at least one prior MM therapy (including a proteasome
inhibitor or immunomodulatory drug). Patients with
an active infection, history of significant medical illness
within the past six months, or history of other active ma-
lignancies within the past three years were excluded.
Patients had received a median of five prior therapies
(range = 1-15 therapies), and most (61%) had disease
refractory to both bortezomib and lenalidomide. Thirty
patients (46%) were positive for t(11;14). “Although the
study did not select for t(11;14) myeloma,” the authors
5”
75”
explained, “a high proportion of patients with this ab-
normality were enrolled … based on previously available
data showing activity of venetoclax in t(11;14)-positive
myeloma cells.”
After a two-week lead-in period with weekly dose
escalation to minimize the risk of tumor lysis syndrome,
venetoclax was administered daily at 300, 600, 90